How do you identify the right patient for a given drug? How do you select your population to ensure that the signal of benefit is most pronounced? The boundaries of breast cancer biomarker development are being increasingly pushed to help power better decisions for developers, oncologists and, ultimately, for breast cancer patients.
This webinar will explore a range of topics, including:
- Recent and emerging breast cancer biomarkers
- Platforms for breast cancer biomarker identification and characterization (such as tumor microenvironment, tumor infiltrating lymphocytes, liquid biopsies, immune and digital biomarkers)
- The translation of breast cancer biomarkers into the development of new breast cancer therapies
- The benefits of parallel development of companion diagnostics (CDx) for “day 1 readiness” in securing commercialization for new therapies.
Register for this webinar to learn about the emerging role of immune and digital biomarkers, and the benefits of parallel development of therapeutics and CDx.
Kamal Veer Singh Saini, MBBS, MD, MRCP (UK), DM (Med Onc), Executive Medical Director, Labcorp Oncology
Kamal Veer Singh Saini, MD, is Executive Medical Director, Labcorp Oncology, based in Brussels, Belgium. Kamal is a board-certified medical oncologist, with an active license to practice in the UK. He contributes to the scientific strategic leadership of the Oncology area at Labcorp, and provides clinical and medical expertise to project teams and other Labcorp departments on clients’ drug development projects.
Kamal brings more than 15 years of experience in clinical research and development. He previously served as Associate Scientific Director for an academic research organization and as Medical Advisor, for the Institute Jules Bordet, Brussels. The author or co-author of several peer-reviewed journal articles, Kamal joined Labcorp in June 2015.Message Presenter
Maria J. Prendes, PhD, MS, Head of Oncology Biomarker Solution Center, LabCorp Oncology
Dr. Maria Prendes leads the Biomarker Solution Center oncology therapeutic team and works with clients to guide the selection, characterization and development of biomarkers for their clinical trials. Her responsibilities also include supporting companion diagnostics (CDx) development efforts.
Specializing in the fields of immuno-oncology, cancer genetics, cancer biology and molecular oncology, Dr. Prendes has more than 15 years of experience in drug development where she directed research for the identification of new clinical biomarkers in oncology as well as designed, developed and characterized antibodies against specific biomarker targets to be used as therapeutic agents and for development of CDx assays. She is the holder of multiple US patents and has authored and co-authored numerous journal articles.Message Presenter
Who Should Attend?
This webinar will be of interest to oncology drug developers, especially those in biotech or leading pharma working on biomarker identification and development, with relevant job titles including:
- Translational Medicine Professionals
- Medical Affairs Professionals
- Medical Monitors
What You Will Learn
This webinar will explore how Labcorp Oncology is responding to patient uniqueness through the development of cutting-edge platforms for biomarker identification for oncology products, including OmniSeq Insight™. The presenters will discuss how the company is reducing time to market and development risk.
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.